Samples

Proposed guidelines kick industry off campus

Proposed guidelines kick industry off campus

By

Pew Charitable Trust's proposed conflict of interest guidelines could mean even less face time for sales reps and less industry money for CME programs.

Business briefs: Gilead, Boehringer, Rx sample ban

Gilead's Striblid faces hurdle in Germany, Boehringer and Roche team up for companion diagnostic effort and Wisconsin hospital system says no to samples

Business briefs: Lundbeck, FDA, Tower Watson and National Business Group Study, Merck

Lundbeck and Otsuka deepen their Abilify co-promotion partnership; study finds FDA clinical trial rule isn't sticking; another study confirms that employees are paying more for health insurance as employers pay less; Merck appoints new R&D chief

Sales forces shrank in 2011, but not everywhere

By

Pharmas shrank their US sales forces by 7% between 2010 and 2011, but the pain wasn't shared evenly between the biggest of pharmas, as a number of players scaled up.

Pfizer, Crestor tops for global promotional spend in 2011

Pfizer, Crestor tops for global promotional spend in 2011

By

Total global pharma promotional spending fell 3.4% to $92.2 billion in 2011, according to Cegedim Strategic Data, led by a 4.7% decline in detailing spend.

Samples no longer hold sway in pharma marketing mix: study

Samples no longer hold sway in pharma marketing mix: study

By

Over the last four years, drugmakers have slashed support for samples as they rethink what once was an essential part of their marketing mix.

One fourth of family medicine residencies "pharma free," says survey

By

Most US family medicine resident programs have limits on drug industry interaction with doctors, and a quarter shun doctor-company contacts altogether, said a survey by Georgetown University Medical Center and the American Medical Student Association.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.